A 73-Year-Old Man with EGFR+ NSCLC

Joshua K. Sabari, MD, reviews the patient profile of a 73-year-old patient with EGFR+ non–small cell lung cancer.

A medical oncologist provides an overview of treatment options available for patients with EGFR+ non–small cell lung cancer.

Joshua K. Sabari, MD, reviews clinical trial data from FLAURA2 on osimertinib plus chemotherapy in patients with EGFR-mutated advanced lung cancer.

An overview of recent data from the MARIPOSA trial investigating amivantamab plus lazertinib in patients with EGFR-positive advanced lung cancer.

An expert on EGFR+ non–small cell lung cancer discusses factors that influence treatment decisions.

Expert insights on the treatment of patients with non–small cell lung cancer positive for EGFR mutations and what the PAPILLON study seeks to address.

Joshua K. Sabari, MD, offers key takeaways on treating patients with EGFR+ non–small cell lung cancer, highlighting the safety profile.